Share
Share today's newsletter with a colleague and get credit if they sign up for SmartBrief.
Referral Count:
 
0

Story being shared
Employee complaint lands GSK in hot water with U.K. agency
The U.K. Prescriptions Medicine Code of Practice Authority ruled that GlaxoSmithKline violated its code of conduct in promotions for Revolade, a drug to treat the bleeding disorder immune thrombocytopenic purpura. A Glaxo employee told the association that a Glaxo sales rep had promoted Revolade for myeloid fibrosis to a consultant with the National Health Service through meetings and e-mails, which, the panel ruled, contained confusing language written by the marketing department.

Or we can send an email on your behalf
You must submit valid email addresses only. Use of email addresses is subject to terms of SmartBrief's privacy policy .